Radiotherapy for patients with the human immunodeficiency virus: Are special precautions necessary?

Cancer

Volumn 116, Issue 2, 2010, Pages 273-283

  Housri, Nadine ^a   Yarchoan, Robert ^a   Kaushal, Aradhana ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Acquired immunodeficiency syndrome (AIDS); Antiretroviral therapy; Cancer; Human immunodeficiency virus (HIV); Malignancy; Radiation

Indexed keywords

METHOTREXATE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANUS CANCER; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CD4 LYMPHOCYTE COUNT; COLORECTAL CANCER; DESQUAMATION; ESOPHAGITIS; GASTROINTESTINAL TOXICITY; HEAD AND NECK CANCER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTENSITY MODULATED RADIATION THERAPY; KAPOSI SARCOMA; LARYNX CANCER; LUNG CANCER; MEDICAL LITERATURE; MUCOSA INFLAMMATION; NEUTROPENIA; NON SEMINOMATOUS GERMINOMA; NONHODGKIN LYMPHOMA; ODYNOPHAGIA; OPPORTUNISTIC INFECTION; PRACTICE GUIDELINE; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RADIOSENSITIVITY; REVIEW; SALIVARY GLAND DISEASE; SEMINOMA; SKIN TOXICITY; TREATMENT FAILURE; UROGENITAL TRACT DISEASE; UTERINE CERVIX CANCER;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; HIV INFECTIONS; HUMANS; NEOPLASMS; RADIATION TOLERANCE; RADIOTHERAPY; RISK FACTORS;

EID: 75649147036     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24878     Document Type: Review

References (100)

1. Longo DL, Steis RG, Lane HC, et al. Malignancies in the AIDS patient: natural history, treatment strategies, and preliminary results. Ann N Y Acad Sci. 1984;437:421-430.
2. International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst. 2000;92:1823-1830.
3. Patel P, Hanson DL, Sullivan PS, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med. 2008;148:728-736.
4. Engels EA, Pfeiffer RM, Goedert JJ, et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS. 2006;20:1645-1654.
5. Burgi A, Brodine S, Wegner S, et al. Incidence and Risk Factors for the Occurrence of Non-AIDS-Defining Cancers Among Human Immunodeficiency Virus-Infected Individuals. New York: John Wiley & Sons Inc; 2005:1505-1511.
6. Ebell MH, Siwek J, Weiss BD, et al. Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. Am Fam Physician. 2004;69:548-556.
7. Nisce LZ, Safai B. Radiation therapy of Kaposi's sarcoma in AIDS. Memorial Sloan-Kettering experience. Front Radiat Ther Oncol. 1985;19:133-137.
8. Cooper JS, Fried PR. Defining the role of radiation therapy in the management of epidemic Kaposi's sarcoma. Int J Radiat Oncol Biol Phys. 1987;13:35-39.
9. Formenti SC, Chak L, Gill P, et al. Increased radiosensitivity of normal tissue fibroblasts in patients with acquired immunodeficiency syndrome (AIDS) and with Kaposi's sarcoma. Int J Radiat Biol. 1995;68:411-412.
10. Vallis KA. Glutathione deficiency and radiosensitivity in AIDS patients. Lancet. 1991;337:918-919.
11. Sun Y, Huang YC, Xu QZ, et al. HIV-1 Tat depresses DNA-PK(CS) expression and DNA repair, and sensitizes cells to ionizing radiation. Int J Radiat Oncol Biol Phys. 2006;65:842-850.
12. Chak LY, Gill PS, Levine AM, et al. Radiation therapy for acquired immunodeficiency syndrome-related Kaposi's sarcoma. J Clin Oncol. 1988;6:863-867.
13. Cooper JS, Fried PR. Toxicity of oral radiotherapy in patients with acquired immunodeficiency syndrome. Arch Otolaryngol Head Neck Surg. 1987;113:327-328.
14. Caccialanza M, Marca S, Piccinno R, et al. Radiotherapy of classic and human immunodeficiency virus-related Kaposi's sarcoma: results in 1482 lesions. J Eur Acad Dermatol Venereol. 2008;22:297-302.
15. Chang Y, Cesarman E, Pessin M, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science. 1994;266:1865-1869.
16. Watkins EB, Findlay P, Gelmann E, et al. Enhanced mucosal reactions in AIDS patients receiving oropharyngeal irradiation. Int J Radiat Oncol Biol Phys. 1987;13:1403-1408.
17. Singh NB, Lakier RH, Donde B. Hypofractionated radiation therapy in the treatment of epidemic Kaposi sarcoma - a prospective randomized trial. Radiother Oncol. 2008;88: 211-216.
18. Yarchoan R. Therapy for Kaposi's sarcoma: recent advances and experimental approaches. J Acquir Immune Defic Syndr. 1999;21(suppl 1):S66-S73.
19. Yarchoan R, Tosato G, Little RF. Therapy insight: AIDSrelated malignancies - the influence of antiviral therapy on pathogenesis and management. Nat Clin Pract Oncol. 2005; 2:406-415; quiz 423.
20. Segura Huerta A, Lopez Tendero P, Romera Barroso B, et al. [Non-Hodgkin lymphomas with systemic presentation in patients with HIV infection. Clinical and prognostic factors in a series evaluated before the introduction of the highly active antiretroviral therapy (HAART)]. Rev Clin Esp. 2004;204:303-307.
21. Kaplan LD, Straus DJ, Testa MA, et al. Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med. 1997;336:1641-1648.
22. Little RF, Pittaluga S, Grant N, et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood. 2003;101: 4653-4659.
23. Ratner L, Lee J, Tang S, et al. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol. 2001;19:2171-2178.
24. Kaplan LD, Lee JY, Ambinder RF, et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood. 2005;106:1538-1543.
25. Schultz C, Scott C, Sherman W, et al. Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: initial report of radiation therapy oncology group protocol 88-06. J Clin Oncol. 1996;14:556-564.
26. Newell ME, Hoy JF, Cooper SG, et al. Human immunodeficiency virus-related primary central nervous system lymphoma: factors influencing survival in 111 patients. Cancer. 2004;100:2627-2636.
27. Skiest DJ, Crosby C. Survival is prolonged by highly active antiretroviral therapy in AIDS patients with primary central nervous system lymphoma. AIDS. 2003;17:1787-1793.
28. Gerstner E, Batchelor T. Primary CNS lymphoma. Expert Rev Anticancer Ther. 2007;7:689-700.
29. Jacomet C, Girard PM, Lebrette MG, et al. Intravenous methotrexate for primary central nervous system non-Hodgkin's lymphoma in AIDS. AIDS. 1997;11:1725-1730.
30. Forsyth PA, Yahalom J, DeAngelis LM. Combined-modality therapy in the treatment of primary central nervous system lymphoma in AIDS. Neurology. 1994;44:1473-1479.
31. Stier E. Cervical neoplasia and the HIV-infected patient. Hematol Oncol Clin North Am. 2003;17:873-887.
32. Gichangi P, Bwayo J, Estambale B, et al. HIV impact on acute morbidity and pelvic tumor control following radiotherapy for cervical cancer. Gynecol Oncol. 2006;100:405-411.
33. Shrivastava SK, Engineer R, Rajadhyaksha S, et al. HIV infection and invasive cervical cancers, treatment with radiation therapy: toxicity and outcome. Radiother Oncol. 2005; 74:31-35.
34. Maiman M. Management of cervical neoplasia in human immunodeficiency virus-infected women. J Natl Cancer Inst Monogr. 1998;23:43-49.
35. Oehler-Janne C, Huguet F, Provencher S, et al. HIV-specific differences in outcome of squamous cell carcinoma of the anal canal: a multicentric cohort study of HIV-positive patients receiving highly active antiretroviral therapy. J Clin Oncol. 2008;26:2550-2557.
36. Holland JM, Swift PS. Tolerance of patients with human immunodeficiency virus and anal carcinoma to treatment with combined chemotherapy and radiation therapy. Radiology. 1994;193:251-254.
37. Kim JH, Sarani B, Orkin BA, et al. HIV-positive patients with anal carcinoma have poorer treatment tolerance and outcome than HIV-negative patients. Dis Colon Rectum. 2001;44:1496-1502.
38. Peddada AV, Smith DE, Rao AR, et al. Chemotherapy and low-dose radiotherapy in the treatment of HIVinfected patients with carcinoma of the anal canal. Int J Radiat Oncol Biol Phys. 1997;37:1101-1105.
39. Chadha M, Rosenblatt EA, Malamud S, et al. Squamouscell carcinoma of the anus in HIV-positive patients. Dis Colon Rectum. 1994;37:861-865.
40. Cleator S, Fife K, Nelson M, et al. Treatment of HIV-associated invasive anal cancer with combined chemoradiation. Eur J Cancer. 2000;36:754-758.
41. Hoffman R, Welton ML, Klencke B, et al. The significance of pretreatment CD4 count on the outcome and treatment tolerance of HIV-positive patients with anal cancer. Int J Radiat Oncol Biol Phys. 1999;44:127-131.
42. Wexler A, Berson AM, Goldstone SE, et al. Invasive anal squamous-cell carcinoma in the HIV-positive patient: outcome in the era of highly active antiretroviral therapy. Dis Colon Rectum. 2008;51:73-81.
43. Blazy A, Hennequin C, Gornet JM, et al. Anal carcinomas in HIV-positive patients: high-dose chemoradiotherapy is feasible in the era of highly active antiretroviral therapy. Dis Colon Rectum. 2005;48:1176-1181.
44. Edelman S, Johnstone PA. Combined modality therapy for HIV-infected patients with squamous cell carcinoma of the anus: outcomes and toxicities. Int J Radiat Oncol Biol Phys. 2006;66:206-211.
45. Seo Y, Kinsella MT, Reynolds HL, et al. Outcomes of chemoradiotherapy with 5-Fluorouracil and mitomycin C for anal cancer in immunocompetent versus immunodeficient patients. Int J Radiat Oncol Biol Phys. 2009;75:143-149.
46. Roohipour R, Patil S, Goodman KA, et al. Squamous-cell carcinoma of the anal canal: predictors of treatment outcome. Dis Colon Rectum. 2008;51:147-153.
47. Klas JV, Rothenberger DA, Wong WD, et al. Malignant tumors of the anal canal: the spectrum of disease, treatment, and outcomes. Cancer. 1999;85:1686-1693.
48. Salama JK, Mell LK, Schomas DA, et al. Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience. J Clin Oncol. 2007;25:4581-4586.
49. Oehler-Janne C, Seifert B, Lutolf UM, et al. Local tumor control and toxicity in HIV-associated anal carcinoma treated with radiotherapy in the era of antiretroviral therapy. Radiat Oncol. 2006;1:29.
50. Ajani JA, Winter KA, Gunderson LL, et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA. 2008;299:1914-1921.
51. Hammer SM, Eron JJ Jr, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA. 2008;300:555-570.
52. Levinson A, Nagler EA, Lowe FC. Approach to management of clinically localized prostate cancer in patients with human immunodeficiency virus. Urology. 2005;65:91-94.
53. O'Connor JK, Nedzi LA, Zakris EL. Prostate adenocarcinoma and human immunodeficiency virus: report of 3 cases and review of the literature. Clin Genitourin Cancer. 2006;5:85-88.
54. Ng T, Stein NF, Kaminetsky J, et al. Preliminary results of radiation therapy for prostate cancer in human immunodeficiency virus-positive patients. Urology. 2008;72: 1135-1138; discussion 1138.
55. Pantanowitz L, Bohac G, Cooley TP, et al. Human immunodeficiency virus-associated prostate cancer: clinicopathological findings and outcome in a multi-institutional study. BJU Int. 2008;101:1519-1523.
56. Cadranel J, Garfield D, Lavole A, et al. Lung cancer in HIV infected patients: facts, questions and challenges. Thorax. 2006;61:1000-1008.
57. Engels EA, Brock MV, Chen J, et al. Elevated incidence of lung cancer among HIV-infected individuals. J Clin Oncol. 2006;24:1383-1388.
58. Clifford GM, Polesel J, Rickenbach M, et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst. 2005;97:425-432.
59. Bazoes A, Bower M, Powles T. Smoke and mirrors: HIV-related lung cancer. Curr Opin Oncol. 2008;20:529-533.
60. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21:109-122.
61. Costleigh BJ, Miyamoto CT, Micaily B, et al. Heightened sensitivity of the esophagus to radiation in a patient with AIDS. Am J Gastroenterol. 1995;90:812-814.
62. Leigh BR, Lau DH. Severe esophageal toxicity after thoracic radiation therapy for lung cancer associated with the human immunodeficiency virus: a case report and review of the literature. Am J Clin Oncol. 1998; 21:479-481.
63. Spano JP, Massiani MA, Bentata M, et al. Lung cancer in patients with HIV Infection and review of the literature. Med Oncol. 2004;21:109-115.
64. Tirelli U, Spina M, Sandri S, et al. Lung carcinoma in 36 patients with human immunodeficiency virus infection. The Italian Cooperative Group on AIDS and Tumors. Cancer. 2000;88:563-569.
65. Bower M, Powles T, Nelson M, et al. HIV-related lung cancer in the era of highly active antiretroviral therapy. AIDS. 2003;17:371-375.
66. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst. 2008;100:261-269.
67. Kao GD, Devine P, Mirza N. Oral cavity and oropharyngeal tumors in human immunodeficiency virus-positive patients: acute response to radiation therapy. Arch Otolaryngol Head Neck Surg. 1999;125:873-876.
68. Harris MA, Wise MS, Bonington A, et al. Case report: radical radiotherapy for early laryngeal cancer in a patient with human immunodeficiency virus: no evidence of increased toxicity. Br J Radiol. 2004;77:519-520.
69. Goedert JJ, Cote TR, Virgo P, et al. Spectrum of AIDS-associated malignant disorders. Lancet. 1998;351:1833-1839.
70. Bernardi D, Salvioni R, Vaccher E, et al. Testicular germ cell tumors and human immunodeficiency virus infection: a report of 26 cases. Italian Cooperative Group on AIDS and Tumors. J Clin Oncol. 1995;13:2705-2711.
71. Fizazi K, Amato RJ, Beuzeboc P, et al. Germ cell tumors in patients infected by the human immunodeficiency virus. Cancer. 2001;92:1460-1467.
72. Hentrich MU, Brack NG, Schmid P, et al. Testicular germ cell tumors in patients with human immunodeficiency virus infection. Cancer. 1996;77:2109-2116.
73. Powles T, Bower M, Daugaard G, et al. Multicenter study of human immunodeficiency virus-related germ cell tumors. J Clin Oncol. 2003;21:1922-1927.
74. Timmerman JM, Northfelt DW, Small EJ. Malignant germ cell tumors in men infected with the human immunodeficiency virus: natural history and results of therapy. J Clin Oncol. 1995;13:1391-1397.
75. Harshany ML, Polhemus ME. Effects of adjuvant radiotherapy for testicular cancer on CD4+ cell count in HIV-positive patients: a case report. AIDS Read. 2004;14:189-190, 192-193.
76. Beuzeboc P, Quang TN, Flam TA, et al. [2 cases of testicular seminoma associated with HIV infection. Analysis of treatment tolerance]. Bull Cancer. 1989;76: 729-732.
77. Palmer MC, Mador DR, Venner PM. Testicular seminoma associated with the acquired immunodeficiency syndrome and acquired immunodeficiency syndrome related complex: 2 case reports. J Urol. 1989;142:128-130.
78. Wilkinson M, Carroll PR. Testicular carcinoma in patients positive and at risk for human immunodeficiency virus. J Urol. 1990;144:1157-1159.
79. Powles T, Bower M, Shamash J, et al. Outcome of patients with HIV-related germ cell tumours: a case-control study. Br J Cancer. 2004;90:1526-1530.
80. Pantanowitz L, Dezube BJ. Reasons for a deficit of breast cancer among HIV-infected patients. J Clin Oncol. 2004; 22:1347-1348; author reply 1349-1350.
81. Frisch M, Biggar RJ, Engels EA, et al. Association of cancer with AIDS-related immunosuppression in adults. JAMA. 2001;285:1736-1745.
82. Hurley J, Franco S, Gomez-Fernandez C, et al. Breast cancer and human immunodeficiency virus: a report of 20 cases. Clin Breast Cancer. 2001;2:215-220; discussion 221.
83. Oluwole SF, Ali AO, Shafaee Z, et al. Breast cancer in women with HIV/AIDS: report of 5 cases with a review of the literature. J Surg Oncol. 2005;89:23-27.
84. Voutsadakis IA, Silverman LR. Breast cancer in HIV-positive women: a report of 4 cases and review of the literature. Cancer Invest. 2002;20:452-457.
85. Rose PG, Fraire AE. Multiple primary gynecologic neoplasms in a young HIV-positive patient. J Surg Oncol. 1993;53:269-272.
86. Widrick P, Boguniewicz A, Nazeer T, et al. Breast cancer in a man with human immunodeficiency virus infection. Mayo Clin Proc. 1997;72:761-764.
87. Wasserberg N, Nunoo-Mensah JW, Gonzalez-Ruiz C, et al. Colorectal cancer in HIV-infected patients: a case control study. Int J Colorectal Dis. 2007;22:1217-1221.
88. Yeguez JF, Martinez SA, Sands DR, et al. Colorectal malignancies in HIV-positive patients. Am Surg. 2003; 69:981-987.
89. Cappell MS, Yao F, Cho KC. Colonic adenocarcinoma associated with the acquired immune deficiency syndrome. Cancer. 1988;62:616-619.
90. De Ruysscher D, Waer M, Vandeputte M, et al. Changes of lymphocyte subsets after local irradiation for early stage breast cancer and seminoma testis: long-term increase of activated (HLA-DR+) T cells and decrease of "naive" (CD4-CD45R) T lymphocytes. Eur J Cancer. 1992;28A: 1729-1734.
91. Haas GS, Halperin E, Doseretz D, et al. Differential recovery of circulating T cell subsets after nodal irradiation for Hodgkin's disease. J Immunol. 1984;132:1026-1030.
92. Nakayama Y, Makino S, Fukuda Y, et al. Varied effects of thoracic irradiation on peripheral lymphocyte subsets in lung cancer patients. Intern Med. 1995;34:959-965.
93. Yang SJ, Rafla S, Youssef E, et al. Changes in T-cell subsets after radiation therapy. Radiology. 1988;168:537-540.
94. Tam HK, Zhang ZF, Jacobson LP, et al. Effect of highly active antiretroviral therapy on survival among HIV-infected men with Kaposi sarcoma or non-Hodgkin lymphoma. Int J Cancer. 2002;98:916-922.
95. Gupta AK, Cerniglia GJ, Mick R, et al. HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo. Cancer Res. 2005;65:8256-8265.
96. Brunner TB, Geiger M, Grabenbauer GG, et al. Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer. J Clin Oncol. 2008;26:2699-2706.
97. Plastaras JP, Vapiwala N, Ahmed MS, et al. Validation and toxicity of PI3K/Akt pathway inhibition by HIV protease inhibitors in humans. Cancer Biol Ther. 2008;7:628-635.
98. Swift PS. Radiation therapy for malignancies in the setting of HIV disease. Oncology (Williston Park). 1997;11:683-694; discussion 694, 701-702.
99. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Washington, DC: Department of Health and Human Services; 2008.
100. Silverberg MJ, Neuhaus J, Bower M, et al. Risk of cancers during interrupted antiretroviral therapy in the SMART study. AIDS. 2007;21:1957-1963.